

Manuela Vaneckova

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/907010/publications.pdf>

Version: 2024-02-01

44
papers

861
citations

471509

17
h-index

526287

27
g-index

45
all docs

45
docs citations

45
times ranked

1285
citing authors

#	ARTICLE	IF	CITATIONS
1	Gray matter atrophy patterns in multiple sclerosis: A 10-year source-based morphometry study. <i>NeuroImage: Clinical</i> , 2018, 17, 444-451.	2.7	58
2	Characteristics of motor speech phenotypes in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 19, 62-69.	2.0	58
3	Neurofilament levels are associated with blood-brain barrier integrity, lymphocyte extravasation, and risk factors following the first demyelinating event in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 220-231.	3.0	55
4	Neurological software tool for reliable atrophy measurement (NeuroSTREAM) of the lateral ventricles on clinical-quality T2-FLAIR MRI scans in multiple sclerosis. <i>NeuroImage: Clinical</i> , 2017, 15, 769-779.	2.7	48
5	Serum lipid profile changes predict neurodegeneration in interferon- β 1a-treated multiple sclerosis patients. <i>Journal of Lipid Research</i> , 2017, 58, 403-411.	4.2	43
6	Serum neurofilament light chain reflects inflammation-driven neurodegeneration and predicts delayed brain volume loss in early stage of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 52-60.	3.0	41
7	Lifespan normative data on rates of brain volume changes. <i>Neurobiology of Aging</i> , 2019, 81, 30-37.	3.1	40
8	Is no evidence of disease activity an achievable goal in MS patients on intramuscular interferon beta-1a treatment over long-term follow-up?. <i>Multiple Sclerosis Journal</i> , 2017, 23, 242-252.	3.0	39
9	Combining clinical and magnetic resonance imaging markers enhances prediction of 12-year disability in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017, 23, 51-61.	3.0	39
10	Pathological cut-offs of global and regional brain volume loss in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019, 25, 541-553.	3.0	32
11	Progressive Chronic Retinal Axonal Loss Following Acute Methanol-induced Optic Neuropathy: Four-Year Prospective Cohort Study. <i>American Journal of Ophthalmology</i> , 2018, 191, 100-115.	3.3	30
12	Establishing pathological cut-offs for lateral ventricular volume expansion rates. <i>NeuroImage: Clinical</i> , 2018, 18, 494-501.	2.7	26
13	Cognitive clinico-radiological paradox in early stages of multiple sclerosis. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 81-91.	3.7	26
14	Leukotriene-mediated neuroinflammation, toxic brain damage, and neurodegeneration in acute methanol poisoning. <i>Clinical Toxicology</i> , 2017, 55, 249-259.	1.9	24
15	Monitoring of radiologic disease activity by serum neurofilaments in MS. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2020, 7, .	6.0	24
16	Multisystem mitochondrial diseases due to mutations in mtDNA-encoded subunits of complex I. <i>BMC Pediatrics</i> , 2020, 20, 41.	1.7	23
17	A Novel Semiautomated Pipeline to Measure Brain Atrophy and Lesion Burden in Multiple Sclerosis: A Long-Term Comparative Study. <i>Journal of Neuroimaging</i> , 2017, 27, 620-629.	2.0	20
18	Clinical and genetic determinants of chronic visual pathway changes after methanol - induced optic neuropathy: four-year follow-up study. <i>Clinical Toxicology</i> , 2019, 57, 387-397.	1.9	20

#	ARTICLE	IF	CITATIONS
19	Additive Effect of Spinal Cord Volume, Diffuse and Focal Cord Pathology on Disability in Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2019, 10, 820.	2.4	16
20	Brain volumetric correlates of dysarthria in multiple sclerosis. <i>Brain and Language</i> , 2019, 194, 58-64.	1.6	16
21	Evolution of Brain Volume Loss Rates in Early Stages of Multiple Sclerosis. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2021, 8, .	6.0	15
22	Gait and Balance Impairment after Acute Methanol Poisoning. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2018, 122, 176-182.	2.5	15
23	Neuroinflammation markers and methyl alcohol induced toxic brain damage. <i>Toxicology Letters</i> , 2018, 298, 60-69.	0.8	13
24	Long-term effectiveness of natalizumab on MRI outcomes and no evidence of disease activity in relapsing-remitting multiple sclerosis patients treated in a Czech Republic real-world setting: A longitudinal, retrospective study. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 46, 102543.	2.0	13
25	Deep Gray Matter Iron Content in Neuromyelitis Optica and Multiple Sclerosis. <i>BioMed Research International</i> , 2020, 2020, 1-6.	1.9	13
26	Methanol Poisoning as an Acute Toxicological Basal Ganglia Lesion Model: Evidence from Brain Volumetry and Cognition. <i>Alcoholism: Clinical and Experimental Research</i> , 2019, 43, 1486-1497.	2.4	12
27	Anterior hippocampus volume loss in narcolepsy with cataplexy. <i>Journal of Sleep Research</i> , 2019, 28, e12785.	3.2	12
28	The impact of co-morbidities on a 6-year survival after methanol mass poisoning outbreak: possible role of metabolic formaldehyde. <i>Clinical Toxicology</i> , 2020, 58, 241-253.	1.9	12
29	Role of activation of lipid peroxidation in the mechanisms of acute methanol poisoning. <i>Clinical Toxicology</i> , 2018, 56, 893-903.	1.9	10
30	Neuroprotective associations of apolipoproteins A-I and A-II with neurofilament levels in early multiple sclerosis. <i>Journal of Clinical Lipidology</i> , 2020, 14, 675-684.e2.	1.5	8
31	White matter alteration and cerebellar atrophy are hallmarks of brain MRI in alpha-mannosidosis. <i>Molecular Genetics and Metabolism</i> , 2021, 132, 189-197.	1.1	8
32	Is Chelation Therapy Efficient for the Treatment of Intravenous Metallic Mercury Intoxication?. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2017, 120, 628-633.	2.5	7
33	Combining clinical and magnetic resonance imaging markers enhances prediction of 12-year employment status in multiple sclerosis patients. <i>Journal of the Neurological Sciences</i> , 2018, 388, 87-93.	0.6	7
34	Health-related quality of life determinants in survivors of a mass methanol poisoning outbreak: six-year prospective cohort study. <i>Clinical Toxicology</i> , 2020, 58, 870-880.	1.9	6
35	MRI-based brain volumetry and retinal optical coherence tomography as the biomarkers of outcome in acute methanol poisoning. <i>NeuroToxicology</i> , 2020, 80, 12-19.	3.0	6
36	Interpretation of Brain Volume Increase in Multiple Sclerosis. <i>Journal of Neuroimaging</i> , 2021, 31, 401-407.	2.0	6

#	ARTICLE	IF	CITATIONS
37	Factors influencing daily treatment choices in multiple sclerosis: practice guidelines, biomarkers and burden of disease. <i>Therapeutic Advances in Neurological Disorders</i> , 2020, 13, 175628642097522.	3.5	5
38	The Role of High-Frequency MRI Monitoring in the Detection of Brain Atrophy in Multiple Sclerosis. <i>Journal of Neuroimaging</i> , 2018, 28, 328-337.	2.0	4
39	Markers of nucleic acids and proteins oxidative damage in acute methanol poisoning. <i>Monatshefte für Chemie</i> , 2019, 150, 477-487.	1.8	4
40	Reactive carbonyl compounds, carbonyl stress, and neuroinflammation in methyl alcohol intoxication. <i>Monatshefte für Chemie</i> , 2019, 150, 1723-1730.	1.8	3
41	Efficiency of ¹²³ I-ioflupane SPECT as the marker of basal ganglia damage in acute methanol poisoning: 6-year prospective study. <i>Clinical Toxicology</i> , 2021, 59, 235-245.	1.9	2
42	"The spectrum of MRI findings of progressive multifocal leukoencephalopathy in patients with multiple sclerosis in the Czech Republic". <i>Ceska A Slovenska Neurologie A Neurochirurgie</i> , 2019, 82/115, 381-390.	0.1	1
43	"Magnetic resonance imaging in neuromyelitis optica spectrum disorders". <i>Ceska A Slovenska Neurologie A Neurochirurgie</i> , 2020, 83/116, S20-S30.	0.1	1
44	Reply. <i>American Journal of Ophthalmology</i> , 2018, 195, 247-248.	3.3	0